Article
Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.
Anticancer research - 1 Jan 2000
Jancarikova D, Pesek M, Benesova L, Topolcan O, Holubec L, Minarik M
Abstract excerpt
According to previous reports in the literature, the T790M mutation indicates an acquired resistance to tyrosine kinase inhibitors. The initial positive effect of combination chemotherapy with erlotinib as the first line of treatment correlates with several positive predictors including the type of carcinoma, non-smoking status, occurrence of rash and the presence of exon 19 EGFR gene mutation. The case of a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.